We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-19.32%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$114M
AUM Growth
-$57.2M
Cap. Flow
-$13.7M
Cap. Flow %
-12.06%
Top 10 Hldgs %
77.21%
Holding
33
New
2
Increased
7
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
NEOS
Neos Therapeutics, Inc
NEOS
+$11.2M
2
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
+$7.37M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.39M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$3.23M
5
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
+$2.81M

Top Sells

Rank Stock Value
1
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
+$7.74M
2
AMRN
Amarin Corp
AMRN
+$7.29M
3
BSTC
BioSpecifics Technologies Corp.
BSTC
+$4.05M
4
KALV
KalVista Pharmaceuticals
KALV
+$3.05M
5
CDTX
Cidara Therapeutics
CDTX
+$2.89M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCYX icon
26
SCYNEXIS
SCYX
$35.9M
– –
-5,610
Closed -$539K
SPRO icon
27
Spero Therapeutics
SPRO
$69.5M
– –
-226,444
Closed -$2.38M
SRTS icon
28
Sensus Healthcare
SRTS
$49.6M
– –
-37,858
Closed -$317K
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.35B
– –
-100,000
Closed -$1.32M
VYNT
30
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
– –
-4,096
Closed -$639K
FSTX
31
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-17,763
Closed -$856K
MLNT
32
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
– –
-391,719
Closed -$7.74M
DOVA
33
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-6,900
Closed -$145K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Stonepine Capital Management held 33 positions worth $114M, down 33% from $171M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Stonepine Capital Management withdrew a net $13.7M in Q4 2018, closing 11 positions and reducing 13 holdings. Its most notable exit was Melinta Therapeutics, Inc. Common Stock, an estimated $7.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Affimed worth $2.22M.

  • Stonepine Capital Management's largest Q4 2018 buy was Affimed: 71,408 shares worth $2.22M.
  • Stonepine Capital Management added most to Neos Therapeutics, Inc in Q4 2018, an estimated $11.2M increase.
  • Stonepine Capital Management's biggest Q4 2018 reduction was Amarin Corp, cutting an estimated $7.29M.
  • Stonepine Capital Management fully exited Melinta Therapeutics, Inc. Common Stock in Q4 2018, selling an estimated $7.74M.
  • Stonepine Capital Management's ten largest holdings make up 77% of its $114M portfolio in Q4 2018.
  • Stonepine Capital Management opened 2 new positions and closed 11 in Q4 2018.
  • Stonepine Capital Management's portfolio value fell 33% quarter-over-quarter to $114M.

Based on Stonepine Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.